Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case studyOude Elberink, H. N. G., Jalving, M., Dijkstra, H. & van de Ven, A. A. J. M., 2020, In : Clinical and translational allergy. 10, p. 5
Research output: Contribution to journal › Article › Academic › peer-review
Carboplatin administration can usually be safely continued via a so-called desensitisation protocol when hypersensitivity reactions arise. Severe break-through reactions that occur early during desensitisation are likely to be IgE-mediated; in that case, addition of omalizumab premedication should be strongly considered.
|Journal||Clinical and translational allergy|
|Publication status||Published - 2020|